VIA
CRSP icon

Virtus Investment Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Virtus Investment Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$709K Buy
14,894
+2,838
+24% +$150K 0.2% 176
2025
Q4 		$632K Buy
12,056
+1,291
+12% +$77.3K 0.17% 212
2025
Q3 		$698K Hold
10,765
– – 0.2% 169
2025
Q2 		$524K Buy
10,765
+2,860
+36% +$111K 0.18% 179
2025
Q1 		$269K Buy
+7,905
New +$335K 0.07% 249

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Virtus Investment Advisers's CRSP Position: Q1 2026 in Review

Virtus Investment Advisers increased its CRISPR Therapeutics (CRSP) stake by 24% in Q1 2026, buying an estimated $150K and bringing the position to 14,894 shares worth $709K. The position accounts for 0.2% of the portfolio, ranked #176.

Virtus Investment Advisers first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Virtus Investment Advisers held 14,894 shares of CRISPR Therapeutics worth $709K as of Q1 2026.
  • Virtus Investment Advisers bought 2,838 CRISPR Therapeutics shares in Q1 2026, an estimated $150K.
  • CRISPR Therapeutics made up 0.2% of Virtus Investment Advisers's portfolio in Q1 2026, its #176 holding.
  • Virtus Investment Advisers first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.